ERBB2 and breast carcinoma: Based on the extraordinary results of the Cleopatra Trial in HER2 positive breast cancer [28], it has been speculated that also in GC the addition of pertuzumab (another monoclonal antibody targeting a different HER2 domain than trastuzumab) to trastuzumab itself and platinum-based chemotherapy could improve the ToGA survival rates, leading to JACOB Trial design.